S218: A PHASE I/II STUDY OF GOLIDOCITINIB, A SELECTIVE JAK1 INHIBITOR, IN REFRACTORY OR RELAPSED PERIPHERAL T CELL LYMPHOMA
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843764.15785.8c |
| _version_ | 1797285937718231040 |
|---|---|
| author | W.-S. Kim D.-H. Yoon Y. Song H. Yang J. Cao D. Ji Y. Koh H. Jing H.-S. Eom J.-Y. Kwak W.-S. Lee J.-S. Lee H.-J. Shin J. Jin M. Wang J. Li X. Huang X. Deng Z. Yang J. Zhu |
| author_facet | W.-S. Kim D.-H. Yoon Y. Song H. Yang J. Cao D. Ji Y. Koh H. Jing H.-S. Eom J.-Y. Kwak W.-S. Lee J.-S. Lee H.-J. Shin J. Jin M. Wang J. Li X. Huang X. Deng Z. Yang J. Zhu |
| author_sort | W.-S. Kim |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:11:05Z |
| format | Article |
| id | doaj.art-77e554c83b634611b41271e0b0a12f2d |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:11:05Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-77e554c83b634611b41271e0b0a12f2d2024-03-02T07:47:13ZengWileyHemaSphere2572-92412022-06-01611912010.1097/01.HS9.0000843764.15785.8c202206003-00119S218: A PHASE I/II STUDY OF GOLIDOCITINIB, A SELECTIVE JAK1 INHIBITOR, IN REFRACTORY OR RELAPSED PERIPHERAL T CELL LYMPHOMAW.-S. Kim0D.-H. Yoon1Y. Song2H. Yang3J. Cao4D. Ji5Y. Koh6H. Jing7H.-S. Eom8J.-Y. Kwak9W.-S. Lee10J.-S. Lee11H.-J. Shin12J. Jin13M. Wang14J. Li15X. Huang16X. Deng17Z. Yang18J. Zhu191 Department of Hematology and Oncology, Samsung Medical Center2 Department of Oncology - Hematologic Cancer & BMT center, Asan Medical Center, Seoul, South Korea3 Department of Lymphoma, Peking University Cancer Hospital, Beijing4 Department of Lymphoma, Zhejiang Cancer Hospital, Hangzhou5 Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China5 Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China6 Department of Hemato-Oncology Center, Seoul National University Hospital, Seoul, South Korea7 Department of Hematology, Peking University Third Hospital, Beijing, China8 Center for Hematologic Malignancy, National Cancer Center, Goyang9 Department of Hemato-Oncology Center, Chonbuk National University Hospital, Jeonju10 Department of Hemato-Oncology Center, Inje University Busan Paik Hospital, Busan11 Department of Hematology & Medical Oncology, Seoul National University Bundang Hospital, Seongnam12 Department of Hemato-Oncology Center, Pusan National University Hospital, Busan, South Korea13 Department of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou14 Clinical Development, Dizal Pharmaceutical, Shanghai, China14 Clinical Development, Dizal Pharmaceutical, Shanghai, China14 Clinical Development, Dizal Pharmaceutical, Shanghai, China14 Clinical Development, Dizal Pharmaceutical, Shanghai, China14 Clinical Development, Dizal Pharmaceutical, Shanghai, China3 Department of Lymphoma, Peking University Cancer Hospital, Beijinghttp://journals.lww.com/10.1097/01.HS9.0000843764.15785.8c |
| spellingShingle | W.-S. Kim D.-H. Yoon Y. Song H. Yang J. Cao D. Ji Y. Koh H. Jing H.-S. Eom J.-Y. Kwak W.-S. Lee J.-S. Lee H.-J. Shin J. Jin M. Wang J. Li X. Huang X. Deng Z. Yang J. Zhu S218: A PHASE I/II STUDY OF GOLIDOCITINIB, A SELECTIVE JAK1 INHIBITOR, IN REFRACTORY OR RELAPSED PERIPHERAL T CELL LYMPHOMA HemaSphere |
| title | S218: A PHASE I/II STUDY OF GOLIDOCITINIB, A SELECTIVE JAK1 INHIBITOR, IN REFRACTORY OR RELAPSED PERIPHERAL T CELL LYMPHOMA |
| title_full | S218: A PHASE I/II STUDY OF GOLIDOCITINIB, A SELECTIVE JAK1 INHIBITOR, IN REFRACTORY OR RELAPSED PERIPHERAL T CELL LYMPHOMA |
| title_fullStr | S218: A PHASE I/II STUDY OF GOLIDOCITINIB, A SELECTIVE JAK1 INHIBITOR, IN REFRACTORY OR RELAPSED PERIPHERAL T CELL LYMPHOMA |
| title_full_unstemmed | S218: A PHASE I/II STUDY OF GOLIDOCITINIB, A SELECTIVE JAK1 INHIBITOR, IN REFRACTORY OR RELAPSED PERIPHERAL T CELL LYMPHOMA |
| title_short | S218: A PHASE I/II STUDY OF GOLIDOCITINIB, A SELECTIVE JAK1 INHIBITOR, IN REFRACTORY OR RELAPSED PERIPHERAL T CELL LYMPHOMA |
| title_sort | s218 a phase i ii study of golidocitinib a selective jak1 inhibitor in refractory or relapsed peripheral t cell lymphoma |
| url | http://journals.lww.com/10.1097/01.HS9.0000843764.15785.8c |
| work_keys_str_mv | AT wskim s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT dhyoon s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT ysong s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT hyang s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT jcao s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT dji s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT ykoh s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT hjing s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT hseom s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT jykwak s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT wslee s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT jslee s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT hjshin s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT jjin s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT mwang s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT jli s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT xhuang s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT xdeng s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT zyang s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma AT jzhu s218aphaseiiistudyofgolidocitinibaselectivejak1inhibitorinrefractoryorrelapsedperipheraltcelllymphoma |